Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavel Fridrich

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Therapeutic Advances in Psychopharmacology|July 7, 2018
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trialThomas R E Barnes, Verity Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 5, 2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectivenessThomas Re Barnes, Verity C Leeson, Carol Paton, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Therapeutic Advances in Psychopharmacology|July 7, 2018
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trialThomas R E Barnes, Verity Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 5, 2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectivenessThomas Re Barnes, Verity C Leeson, Carol Paton, et al.
Pageof 1